These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37145440)

  • 1. Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer.
    Freedland SJ; De Hoedt AM; DerSarkissian M; Chang R; Satija A; Nguyen C; Park S; Aillaud A; Drea E; Duh MS; Polascik TJ; Szatrowski T
    Urol Pract; 2021 Jan; 8(1):112-118. PubMed ID: 37145440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
    Yoo M; Nelson RE; Haaland B; Dougherty M; Cutshall ZA; Kohli R; Beckstead R; Kohli M
    J Natl Cancer Inst; 2023 Nov; 115(11):1374-1382. PubMed ID: 37436697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases.
    Wen L; Valderrama A; Costantino ME; Simmons S
    Am Health Drug Benefits; 2019 May; 12(3):142-149. PubMed ID: 31346366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
    Schmidt A; Anton A; Shapiro J; Wong S; Azad A; Kwan E; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua AM; Pook D; Gibbs P; Tran B; Weickhardt A
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):36-42. PubMed ID: 32970925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
    Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
    Bjartell A; Costa L; Kramer G; Zurawski B; Galli L; Werbrouck P; Ecke T; Parikh O; Bennamoun M; Garcia Freire C; Peer A; Ljungberg B; Cicin I; Smith E; Lukac M; Wapenaar R; Chowdhury S
    Eur Urol Open Sci; 2022 Nov; 45():12-22. PubMed ID: 36353661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
    Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
    Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
    Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
    Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI.
    Watson AS; Gagnon R; Batuyong E; Alimohamed N; Lee-Ying R
    Clin Genitourin Cancer; 2022 Oct; 20(5):496.e1-496.e9. PubMed ID: 35599196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.